IMPLANET Reports Revenue of €10.6 Million for the First Nine Months of 2026, up 21%

S. revenue up 32% in Q3 2026 and 45% over the first nine months of 2026 compared with 2025 Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announces its revenue for the third quarter of 2026, ended September 30, 2026, and for the first nine months of 2026. Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: “The growth recorded over the first nine months of 2026 confirms the strength of our commercial momentum, as reflected in the 21% increase in revenue at the end of September.

We have now achieved our ninth consecutive quarter of sustained growth. This performance has been driven by the continued expansion of our Spine Implants and Medical Equipment businesses, with particularly strong momentum in the United States since the beginning of the year. We continue to implement our product and commercial strategy, notably through the commercial rollout of the new JSS hybrid posterior fixation system and the ramp-up of our SMTP business. 73 million in the same period in 2025.

85 million) confirms the growth momentum recorded over the past nine quarters. 02 million in the same period in 2025, driven notably by the very strong performance of the new JSS hybrid posterior fixation system, with associated sales doubling over the period. The Company continued the rollout of its medical equipment distribution business, notably with the SMTP ultrasonic scalpel. 71 million in the same period of the previous year.

Revenue by Region (in € thousands — IFRS standards(2)) 2026 2025 Change % France 3,748 3,179 +18% United States 3,841 2,645 +45% Rest of the World 2,980 2,902 +3% Total nine-month revenue 10,570 8,725 +21% All geographic regions recorded growth in the first nine months of 2026 compared with the same period of the previous year, driven primarily by the strong performance of the new JSS hybrid posterior fixation system. 75 million over the first nine months of 2026. 84 million. 98 million over the first nine months of 2026.

03 million in the third quarter of 2025. This performance was primarily driven by the continued rollout of the new JSS hybrid posterior fixation system. 89 million in the same period in 2025, representing an increase of 46%. Revenue by Region (in € thousands — IFRS standards(3)) 2026 2025 Change % France 1,130 859 +31% United States 1,398 1,062 +32% Rest of the World 907 994 -9% Total Q3 revenue 3,435 2,916 +18% France and the United States both recorded growth in the third quarter of 2026 compared with the same period of the previous year, driven primarily by the very strong performance of the new JSS hybrid posterior fixation system.

13 million in the third quarter of 2026. 40 million, making it the Group's largest geographic market in terms of revenue. 91 million during the quarter, representing a 9% decrease compared with the same period of the previous year, mainly due to an unfavorable comparison base resulting from the first deliveries of JAZZ® in China in 2025. 82 million.

Based on projected cash consumption under its current business assumptions, anticipated commercial developments for fiscal years 2026 and 2027, and the payment facilities granted by the Sanyou Medical Group, the Company believes it is able to cover its operating funding requirements for the next twelve months. The Company is also reviewing several financing alternatives in order to support its growth and address any potential additional funding requirements.

Strategy and Outlook for 2026 Strengthening the Company’s presence in the United States: Reinforce commercial resources available to the existing team through the recruitment of an experienced sales force; Implement the necessary tools to accelerate the rollout of JAZZ® and products co-developed with Sanyou Medical; Strengthen the Company’s direct approach by expanding its scientific team of key opinion leaders.

Deploying all product ranges across strategic geographies: Ensure the commercial rollout of JSS and other Sanyou Medical product lines in France, the United States and internationally; Expand the distribution of the JAZZ® platform in China (the world’s largest spine market by volume) with Sanyou Medical.

Enhancing market momentum and product offering: Position Implanet as the exclusive distributor in Europe and the United States of Sanyou Medical Group’s surgical assistance technologies and those of its partners; Launch the SMTP Quntas range (ultrasonic scalpels with aspiration), marking the brand’s entry into surgical revision and tumor surgery markets; Position IMPLANET as a partner to surgeons and healthcare institutions in the fields of artificial intelligence, cobotics and robotics tailored to its implants. Complete the registration of existing products under the European Medical Device Regulation (MDR) and the FDA 510(k) process.

Next Financial Release Full-Year 2026 Revenue, January 12, 2027, after market close About IMPLANET IMPLANET is a medical technology company that manufactures high-end implants for orthopedic surgery and distributes advanced medical equipment (SMTP and robotics). , Ltd (“Sanyou Medical”) under the technological partnership entered into in November 2022. These product lines are complemented by the ranges offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). IMPLANET’s orthopedic platform is notably based on full product traceability.

S. Food and Drug Administration (FDA), CE marking, ANVISA approval in Brazil, and CFDA approval in China. In 2022, IMPLANET entered into a commercial, technological and financial partnership with SANYOU MEDICAL, the second-largest Chinese manufacturer of medical devices. 5 million in 2025.

S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris. eu)